SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2013 / Cilt: 43 - Sayı: 2

Demonstration of mutations conferring resistance to lamivudine in liver tissue of chronic hepatitis B patients under lamivudine therapy*

İsmail Yaşar AVCI
Levent GÖRENEK
Can Polat EYİGÜN
Hanefi Cem GÜL
Bülent Ahmet BEŞİRBELLİOĞLU
Emine GÜNAL
Ayhan KUBAR
Hakan ERDEM
Ömer COŞKUN
Pages
199–202
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, all liver biopsy specimens of patients with severe liver fibrosis should be analyzed using the molecular technique.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To demonstrate the genotypic lamivudine resistance in liver tissue of patients with negative serum hepatitis B virus (HBV) DNA under long-term lamivudine therapy.
📊
Key Findings & Data:Materials and methods: Fourteen patients (10 patients with elevated alanine aminotransferase and 4 patients under long-term lamivudine therapy for severe liver disease) with undetected serum HBV DNA were included in the study.
💡
Conclusion & Impact:Therefore, all liver biopsy specimens of patients with severe liver fibrosis should be analyzed using the molecular technique.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To demonstrate the genotypic lamivudine resistance in liver tissue of patients with negative serum hepatitis B virus (HBV) DNA under long-term lamivudine therapy. Materials and methods: Fourteen patients (10 patients with elevated alanine aminotransferase and 4 patients under long-term lamivudine therapy for severe liver disease) with undetected serum HBV DNA were included in the study. A liver biopsy was performed for each patient, and HBV DNA extracted from liver tissue was analyzed with TaqMan real-time polymerase chain reaction. Results: Mutations conferring lamivudine resistance were shown for all 14 patients in their liver tissue-extracted HBV DNA. One patient had rtM204V, 4 patients had rtL180M, 2 had rtL180M + rtM204V, 4 had rtL180M + rtM204I, and 3 had rtL180M + rtM204I + rtM204V substitutions. Conclusion: Analyzing mutation in liver tissues of these patients might help demonstrate resistance earlier and prevent delaying of therapeutic modification. Therefore, all liver biopsy specimens of patients with severe liver fibrosis should be analyzed using the molecular technique.

🔖

Cite This Article

AVCI, İ. Y., GÖRENEK, L., EYİGÜN, C. P., GÜL, H. C., BEŞİRBELLİOĞLU, B. A., GÜNAL, E., KUBAR, A., ERDEM, H., COŞKUN, Ö. (2022). Demonstration of mutations conferring resistance to lamivudine in liver tissue of chronic hepatitis B patients under lamivudine therapy*. Turkish Journal of Medical Sciences, Cilt: 43 - Sayı: 2, 199–202. https://ajindex.com/articles/611074

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Dikici B, Uzun H, Gözü A, Fidan M. Prevalence of hepatitis B infection among schoolchildren in southeast Turkey. Turk J Med Sci 2009; 39: 289–93
  2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97–107
  3. Öner S, Yapıcı G, Şaşmaz CT, Kurt AÖ, Buğdaycı R. Hepatitis B, hepatitis C, HIV, and VDRL seroprevalence of blood donors in Mersin, Turkey. Turk J Med Sci 2011; 41: 335–41
  4. Nwankwo E, Momodu I, Umar I, Musa B, Adeleke S. Seroprevalence of major blood-borne infections among blood donors in Kano, Nigeria. Turk J Med Sci 2012; 42: 337–41
  5. Işıkgöz Taşbakan M, Önen Sertöz Ö, Pullukçu H, Özkören Çalık Ş, Sipahi OR, Yamazhan T. Comparison of quality of life in hepatitis B virus carriers versus chronic hepatitis B virus carriers versus the normal population. Turk J Med Sci 2010; 40: 575–83
  6. Takkenberg RB, Weegink CJ, Zaaijer HL, Reesink HW. New developments in antiviral therapy for chronic hepatitis B. Vox Sang 2010; 98: 481–94
  7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529–38
  8. Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K et al. Management of hepatitis B: consensus of the Japan Society of Hepatology 2009. Hepatol Res 2011; 41: 1–21
  9. Tong MJ, Hsu L, Chang PW, Blatt LM. Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update. J Gastroenterol Hepatol 2011; 26: 829–35
  10. Locarnini S. Molecular virology and the development of resistant mutants. Implications for therapy. Semin Liver Dis 2005; 25 (Suppl 1): 9–19
  11. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670–7
  12. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267–73
  13. Damerow H, Yuen L, Wiegand J, Walker C, Bock CT, Locarnini S et al. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol 2010; 82: 1850–8
  14. Bozdayi AM, Eyigun CP, Turkyilmaz AR, Avci IY, Pahsa A, Yurdaydin C. A nov